| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atherosclerosis | 25 | 2025 | 949 | 3.300 |
Why?
|
| Lipoprotein(a) | 10 | 2025 | 140 | 2.660 |
Why?
|
| Lipoproteins | 9 | 2022 | 182 | 1.780 |
Why?
|
| Cholesterol, LDL | 13 | 2022 | 615 | 1.700 |
Why?
|
| Coronary Disease | 14 | 2023 | 628 | 1.640 |
Why?
|
| Cardiovascular Diseases | 18 | 2023 | 2096 | 1.570 |
Why?
|
| Triglycerides | 10 | 2022 | 605 | 1.550 |
Why?
|
| C-Reactive Protein | 12 | 2025 | 450 | 1.340 |
Why?
|
| Biomarkers | 39 | 2025 | 3396 | 1.000 |
Why?
|
| Troponin T | 15 | 2024 | 255 | 0.960 |
Why?
|
| Stroke | 11 | 2023 | 1054 | 0.950 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 8 | 2019 | 91 | 0.880 |
Why?
|
| Cholesterol | 7 | 2018 | 541 | 0.860 |
Why?
|
| Diabetes Mellitus | 4 | 2022 | 890 | 0.840 |
Why?
|
| Brain Ischemia | 4 | 2023 | 267 | 0.840 |
Why?
|
| Lipoproteins, LDL | 4 | 2019 | 118 | 0.740 |
Why?
|
| Risk Factors | 40 | 2025 | 10983 | 0.730 |
Why?
|
| Prospective Studies | 28 | 2024 | 6445 | 0.670 |
Why?
|
| Heart Failure | 12 | 2023 | 2313 | 0.660 |
Why?
|
| Prediabetic State | 2 | 2018 | 67 | 0.650 |
Why?
|
| Apolipoprotein C-III | 3 | 2022 | 46 | 0.640 |
Why?
|
| Middle Aged | 58 | 2025 | 28393 | 0.620 |
Why?
|
| Hypolipidemic Agents | 1 | 2021 | 194 | 0.590 |
Why?
|
| Inflammation | 7 | 2021 | 1480 | 0.580 |
Why?
|
| Apolipoproteins E | 2 | 2018 | 187 | 0.560 |
Why?
|
| Aged | 38 | 2025 | 20897 | 0.540 |
Why?
|
| Natriuretic Peptide, Brain | 8 | 2023 | 324 | 0.470 |
Why?
|
| Hypertension | 2 | 2022 | 1354 | 0.470 |
Why?
|
| Carotid Artery Diseases | 3 | 2014 | 131 | 0.470 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2019 | 750 | 0.470 |
Why?
|
| Lipoprotein Lipase | 1 | 2015 | 61 | 0.450 |
Why?
|
| Incidence | 16 | 2025 | 3344 | 0.450 |
Why?
|
| Risk Assessment | 15 | 2021 | 3691 | 0.440 |
Why?
|
| Metabolic Syndrome | 7 | 2016 | 366 | 0.420 |
Why?
|
| Lipoproteins, HDL | 2 | 2014 | 97 | 0.420 |
Why?
|
| Female | 62 | 2025 | 70349 | 0.410 |
Why?
|
| Male | 63 | 2025 | 64506 | 0.400 |
Why?
|
| Humans | 79 | 2025 | 130444 | 0.390 |
Why?
|
| Apolipoproteins B | 4 | 2019 | 144 | 0.380 |
Why?
|
| Troponin I | 3 | 2024 | 122 | 0.360 |
Why?
|
| Peptide Fragments | 7 | 2023 | 687 | 0.360 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2015 | 1427 | 0.360 |
Why?
|
| Proportional Hazards Models | 10 | 2019 | 1413 | 0.350 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2010 | 165 | 0.350 |
Why?
|
| Phospholipases A | 3 | 2005 | 30 | 0.330 |
Why?
|
| Population Surveillance | 2 | 2021 | 396 | 0.330 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2010 | 122 | 0.330 |
Why?
|
| Spouse Abuse | 1 | 2010 | 15 | 0.320 |
Why?
|
| Apolipoproteins | 3 | 2012 | 69 | 0.320 |
Why?
|
| Cholesterol, HDL | 7 | 2014 | 394 | 0.320 |
Why?
|
| Matrix Metalloproteinases | 1 | 2010 | 62 | 0.310 |
Why?
|
| Atrial Fibrillation | 3 | 2024 | 733 | 0.310 |
Why?
|
| Models, Psychological | 1 | 2010 | 137 | 0.300 |
Why?
|
| Carotid Arteries | 1 | 2010 | 125 | 0.300 |
Why?
|
| Blood Pressure | 6 | 2024 | 1337 | 0.300 |
Why?
|
| Chemokine CCL2 | 4 | 2018 | 112 | 0.290 |
Why?
|
| Monocytes | 3 | 2019 | 336 | 0.260 |
Why?
|
| Models, Biological | 2 | 2010 | 1390 | 0.260 |
Why?
|
| Acute Coronary Syndrome | 1 | 2010 | 247 | 0.250 |
Why?
|
| Obesity | 7 | 2016 | 2383 | 0.250 |
Why?
|
| United States | 20 | 2021 | 11828 | 0.250 |
Why?
|
| Adiponectin | 4 | 2018 | 124 | 0.240 |
Why?
|
| Weight Loss | 5 | 2015 | 526 | 0.240 |
Why?
|
| Coronary Artery Disease | 4 | 2014 | 875 | 0.230 |
Why?
|
| Postprandial Period | 2 | 2016 | 87 | 0.230 |
Why?
|
| Hospitalization | 7 | 2019 | 1927 | 0.220 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2005 | 74 | 0.220 |
Why?
|
| Prognosis | 10 | 2023 | 4904 | 0.210 |
Why?
|
| Albuminuria | 2 | 2022 | 105 | 0.210 |
Why?
|
| Dioxygenases | 1 | 2024 | 70 | 0.200 |
Why?
|
| Myocardial Infarction | 3 | 2024 | 992 | 0.200 |
Why?
|
| Predictive Value of Tests | 6 | 2019 | 2298 | 0.200 |
Why?
|
| Sirolimus | 2 | 2002 | 229 | 0.200 |
Why?
|
| Lipids | 5 | 2014 | 563 | 0.190 |
Why?
|
| Vascular Stiffness | 2 | 2021 | 82 | 0.190 |
Why?
|
| Angiopoietin-like Proteins | 1 | 2022 | 15 | 0.180 |
Why?
|
| Aged, 80 and over | 7 | 2023 | 6771 | 0.180 |
Why?
|
| Galectin 3 | 1 | 2021 | 31 | 0.170 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2020 | 19 | 0.170 |
Why?
|
| Immunosuppressive Agents | 2 | 2002 | 658 | 0.160 |
Why?
|
| Peripheral Arterial Disease | 2 | 2016 | 318 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 599 | 0.160 |
Why?
|
| Cohort Studies | 11 | 2018 | 5083 | 0.160 |
Why?
|
| Renin-Angiotensin System | 1 | 2021 | 106 | 0.160 |
Why?
|
| Life Style | 3 | 2018 | 446 | 0.160 |
Why?
|
| Natriuretic Peptides | 1 | 2019 | 9 | 0.160 |
Why?
|
| Time Factors | 8 | 2021 | 6188 | 0.160 |
Why?
|
| Diet, Western | 1 | 2019 | 20 | 0.160 |
Why?
|
| Blood Glucose | 4 | 2018 | 1103 | 0.150 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2019 | 32 | 0.150 |
Why?
|
| Linear Models | 4 | 2017 | 689 | 0.150 |
Why?
|
| Repressor Proteins | 1 | 2024 | 774 | 0.150 |
Why?
|
| Kidney Transplantation | 2 | 2002 | 562 | 0.150 |
Why?
|
| Case-Control Studies | 6 | 2018 | 3407 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2019 | 3842 | 0.150 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2010 | 37 | 0.150 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2024 | 408 | 0.140 |
Why?
|
| Interleukin-18 | 2 | 2023 | 75 | 0.140 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2018 | 32 | 0.140 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2017 | 10 | 0.140 |
Why?
|
| Protein Precursors | 2 | 2021 | 139 | 0.140 |
Why?
|
| Follow-Up Studies | 9 | 2021 | 5204 | 0.130 |
Why?
|
| Risk | 5 | 2018 | 731 | 0.130 |
Why?
|
| Adipokines | 1 | 2018 | 121 | 0.130 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 535 | 0.130 |
Why?
|
| Fatty Acids | 1 | 2019 | 378 | 0.130 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2014 | 98 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2014 | 2846 | 0.130 |
Why?
|
| Interleukin-6 | 4 | 2024 | 414 | 0.120 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 373 | 0.120 |
Why?
|
| Heart Ventricles | 1 | 2021 | 757 | 0.120 |
Why?
|
| Alzheimer Disease | 1 | 2024 | 876 | 0.120 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2017 | 204 | 0.120 |
Why?
|
| Cell-Derived Microparticles | 1 | 2016 | 26 | 0.120 |
Why?
|
| DNA-Binding Proteins | 1 | 2024 | 1976 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2016 | 783 | 0.120 |
Why?
|
| White Matter | 1 | 2017 | 219 | 0.110 |
Why?
|
| Sensitivity and Specificity | 6 | 2019 | 2111 | 0.110 |
Why?
|
| Diabetic Angiopathies | 1 | 2015 | 67 | 0.110 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2014 | 32 | 0.110 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 229 | 0.110 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 336 | 0.110 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2014 | 49 | 0.110 |
Why?
|
| Cardiomyopathies | 2 | 2016 | 515 | 0.110 |
Why?
|
| Subtilisins | 1 | 2014 | 11 | 0.110 |
Why?
|
| Neurodegenerative Diseases | 1 | 2017 | 289 | 0.110 |
Why?
|
| Aspartate Aminotransferases | 1 | 2014 | 81 | 0.100 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 147 | 0.100 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 1608 | 0.100 |
Why?
|
| Cross-Sectional Studies | 5 | 2021 | 3803 | 0.100 |
Why?
|
| Alanine Transaminase | 1 | 2014 | 157 | 0.100 |
Why?
|
| Athletes | 1 | 2014 | 72 | 0.100 |
Why?
|
| Particle Size | 1 | 2014 | 136 | 0.100 |
Why?
|
| Lactic Acid | 1 | 2014 | 148 | 0.100 |
Why?
|
| Cognition | 1 | 2019 | 813 | 0.100 |
Why?
|
| Prevalence | 3 | 2017 | 2683 | 0.100 |
Why?
|
| Exome | 1 | 2018 | 1075 | 0.100 |
Why?
|
| Brain Infarction | 1 | 2013 | 28 | 0.100 |
Why?
|
| Adult | 10 | 2022 | 31122 | 0.100 |
Why?
|
| Global Health | 1 | 2018 | 626 | 0.100 |
Why?
|
| Leukoencephalopathies | 1 | 2013 | 62 | 0.090 |
Why?
|
| Calcinosis | 2 | 2014 | 180 | 0.090 |
Why?
|
| Brain | 3 | 2024 | 3188 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2016 | 520 | 0.090 |
Why?
|
| Dyslipidemias | 1 | 2015 | 251 | 0.090 |
Why?
|
| Phospholipases A2 | 3 | 2006 | 30 | 0.090 |
Why?
|
| Overweight | 1 | 2015 | 379 | 0.090 |
Why?
|
| Carotid Artery, Internal | 2 | 2010 | 56 | 0.090 |
Why?
|
| Logistic Models | 2 | 2014 | 1806 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 742 | 0.090 |
Why?
|
| Apolipoprotein B-100 | 2 | 2001 | 36 | 0.090 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 346 | 0.090 |
Why?
|
| Apolipoproteins A | 2 | 2001 | 52 | 0.090 |
Why?
|
| Sex Factors | 4 | 2017 | 1332 | 0.090 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 234 | 0.090 |
Why?
|
| Severity of Illness Index | 4 | 2014 | 3030 | 0.090 |
Why?
|
| Carotid Stenosis | 2 | 2010 | 107 | 0.080 |
Why?
|
| Body Mass Index | 2 | 2014 | 1683 | 0.080 |
Why?
|
| Up-Regulation | 3 | 2019 | 833 | 0.080 |
Why?
|
| Nursing Evaluation Research | 1 | 2010 | 10 | 0.080 |
Why?
|
| Chemokine CCL5 | 1 | 2010 | 53 | 0.080 |
Why?
|
| Adipose Tissue | 2 | 2011 | 495 | 0.080 |
Why?
|
| Dehydroepiandrosterone | 1 | 2010 | 23 | 0.080 |
Why?
|
| Alleles | 1 | 2015 | 1672 | 0.080 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2010 | 41 | 0.080 |
Why?
|
| Carotid Artery, Common | 1 | 2010 | 59 | 0.080 |
Why?
|
| Body Weight | 1 | 2014 | 986 | 0.080 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2010 | 72 | 0.080 |
Why?
|
| Prolactin | 1 | 2010 | 145 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2014 | 556 | 0.080 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2011 | 149 | 0.080 |
Why?
|
| Immunoassay | 3 | 2005 | 125 | 0.080 |
Why?
|
| Hydrocortisone | 1 | 2010 | 217 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 427 | 0.080 |
Why?
|
| Myocardial Revascularization | 1 | 2009 | 100 | 0.070 |
Why?
|
| Women's Health | 1 | 2010 | 141 | 0.070 |
Why?
|
| Dementia | 1 | 2014 | 429 | 0.070 |
Why?
|
| Postmenopause | 2 | 2020 | 148 | 0.070 |
Why?
|
| Age Factors | 4 | 2018 | 2836 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2010 | 938 | 0.070 |
Why?
|
| Fibrosis | 1 | 2010 | 419 | 0.070 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2008 | 23 | 0.070 |
Why?
|
| Liver | 2 | 2011 | 1801 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 3410 | 0.070 |
Why?
|
| Echocardiography | 2 | 2024 | 1124 | 0.070 |
Why?
|
| Phenotype | 2 | 2014 | 4476 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2014 | 1556 | 0.060 |
Why?
|
| Odds Ratio | 4 | 2014 | 1222 | 0.060 |
Why?
|
| Comorbidity | 3 | 2017 | 1587 | 0.060 |
Why?
|
| Health Promotion | 1 | 2010 | 407 | 0.060 |
Why?
|
| Cytokines | 2 | 2010 | 1335 | 0.060 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 1839 | 0.060 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2006 | 112 | 0.060 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 850 | 0.060 |
Why?
|
| Leptin | 3 | 2018 | 217 | 0.060 |
Why?
|
| Cystatin C | 2 | 2016 | 71 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2005 | 227 | 0.050 |
Why?
|
| Immunoblotting | 2 | 2001 | 293 | 0.050 |
Why?
|
| Caveolins | 1 | 2003 | 14 | 0.050 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 110 | 0.050 |
Why?
|
| United Kingdom | 1 | 2024 | 254 | 0.050 |
Why?
|
| Azetidines | 2 | 2013 | 63 | 0.050 |
Why?
|
| Simvastatin | 2 | 2013 | 75 | 0.050 |
Why?
|
| Ezetimibe | 2 | 2013 | 94 | 0.050 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2010 | 674 | 0.050 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2024 | 154 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 291 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2024 | 235 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2006 | 798 | 0.040 |
Why?
|
| Models, Cardiovascular | 2 | 2000 | 165 | 0.040 |
Why?
|
| Lipoproteins, VLDL | 1 | 2001 | 53 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1380 | 0.040 |
Why?
|
| Energy Intake | 1 | 2004 | 499 | 0.040 |
Why?
|
| Mutation | 1 | 2015 | 6134 | 0.040 |
Why?
|
| Pulse Wave Analysis | 1 | 2021 | 53 | 0.040 |
Why?
|
| tau Proteins | 1 | 2024 | 258 | 0.040 |
Why?
|
| India | 1 | 2001 | 243 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2001 | 239 | 0.040 |
Why?
|
| Smoking | 2 | 2016 | 929 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2001 | 188 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2001 | 420 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 1487 | 0.040 |
Why?
|
| Insulin | 3 | 2014 | 1146 | 0.040 |
Why?
|
| Apolipoprotein E4 | 1 | 2019 | 52 | 0.040 |
Why?
|
| Proteins | 1 | 2004 | 1015 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 233 | 0.040 |
Why?
|
| Plasminogen Inactivators | 1 | 2018 | 5 | 0.040 |
Why?
|
| Memory, Episodic | 1 | 2017 | 26 | 0.030 |
Why?
|
| Cerebral Infarction | 1 | 2017 | 47 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2000 | 599 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 153 | 0.030 |
Why?
|
| Factor VIII | 1 | 2017 | 51 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2014 | 1250 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2017 | 249 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 1077 | 0.030 |
Why?
|
| Fibrinogen | 1 | 2017 | 166 | 0.030 |
Why?
|
| Cause of Death | 1 | 2019 | 505 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2016 | 79 | 0.030 |
Why?
|
| von Willebrand Factor | 1 | 2017 | 190 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 561 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2017 | 258 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 955 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 1415 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2017 | 290 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2016 | 177 | 0.030 |
Why?
|
| Physical Fitness | 1 | 2015 | 90 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 367 | 0.030 |
Why?
|
| Retirement | 1 | 2014 | 17 | 0.030 |
Why?
|
| Aging | 1 | 2022 | 1252 | 0.030 |
Why?
|
| Multidetector Computed Tomography | 1 | 2014 | 33 | 0.030 |
Why?
|
| beta 2-Microglobulin | 1 | 2014 | 35 | 0.030 |
Why?
|
| Lipocalins | 1 | 2014 | 31 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2006 | 256 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 889 | 0.030 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2014 | 40 | 0.030 |
Why?
|
| Exercise Test | 1 | 2015 | 234 | 0.030 |
Why?
|
| Football | 1 | 2014 | 36 | 0.030 |
Why?
|
| Glycoproteins | 1 | 1996 | 346 | 0.030 |
Why?
|
| Absorption | 1 | 2013 | 49 | 0.030 |
Why?
|
| Sitosterols | 1 | 2013 | 10 | 0.030 |
Why?
|
| Rosuvastatin Calcium | 1 | 2013 | 42 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2014 | 86 | 0.030 |
Why?
|
| Anthropometry | 1 | 2014 | 188 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2014 | 110 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2014 | 81 | 0.030 |
Why?
|
| Fluorobenzenes | 1 | 2013 | 39 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 767 | 0.030 |
Why?
|
| Niacin | 1 | 2013 | 59 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 1996 | 1053 | 0.020 |
Why?
|
| Biological Assay | 1 | 2014 | 106 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 2015 | 169 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2014 | 169 | 0.020 |
Why?
|
| Selection, Genetic | 1 | 2014 | 156 | 0.020 |
Why?
|
| Femoral Artery | 1 | 2013 | 135 | 0.020 |
Why?
|
| Reference Values | 1 | 2014 | 679 | 0.020 |
Why?
|
| Fasting | 1 | 2014 | 304 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2005 | 641 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 729 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2014 | 738 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2014 | 451 | 0.020 |
Why?
|
| Survival Rate | 1 | 2016 | 2134 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2011 | 49 | 0.020 |
Why?
|
| Diet, Fat-Restricted | 1 | 2011 | 37 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2016 | 1451 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 2011 | 80 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2013 | 294 | 0.020 |
Why?
|
| CD11c Antigen | 1 | 2011 | 40 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 195 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 1996 | 1006 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 471 | 0.020 |
Why?
|
| Mice | 3 | 2019 | 18203 | 0.020 |
Why?
|
| Caloric Restriction | 1 | 2011 | 107 | 0.020 |
Why?
|
| Protein Binding | 2 | 2006 | 1666 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2905 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2013 | 452 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 823 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2005 | 17633 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 1625 | 0.020 |
Why?
|
| Diet, High-Fat | 1 | 2011 | 263 | 0.020 |
Why?
|
| Calcium | 1 | 2014 | 1027 | 0.020 |
Why?
|
| Myocardium | 1 | 2014 | 859 | 0.020 |
Why?
|
| Phantoms, Imaging | 2 | 2000 | 144 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2011 | 221 | 0.020 |
Why?
|
| Animals | 4 | 2019 | 33909 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 4660 | 0.020 |
Why?
|
| Mass Screening | 1 | 2014 | 807 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2008 | 92 | 0.020 |
Why?
|
| Contrast Media | 1 | 2011 | 491 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 2606 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2014 | 1086 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2012 | 683 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 269 | 0.020 |
Why?
|
| Electrochemistry | 1 | 2006 | 25 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 610 | 0.020 |
Why?
|
| Static Electricity | 1 | 2006 | 44 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2011 | 4700 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2006 | 434 | 0.010 |
Why?
|
| Microspheres | 1 | 2005 | 67 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2005 | 201 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2005 | 248 | 0.010 |
Why?
|
| Diet, Reducing | 1 | 2004 | 90 | 0.010 |
Why?
|
| Caveolin 1 | 1 | 2003 | 51 | 0.010 |
Why?
|
| Calibration | 1 | 2003 | 92 | 0.010 |
Why?
|
| Prostatic Hyperplasia | 1 | 2003 | 115 | 0.010 |
Why?
|
| Rabbits | 1 | 2003 | 574 | 0.010 |
Why?
|
| Antibodies | 1 | 2003 | 320 | 0.010 |
Why?
|
| Aminocaproic Acid | 1 | 2001 | 4 | 0.010 |
Why?
|
| Ultracentrifugation | 1 | 2001 | 20 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 2001 | 64 | 0.010 |
Why?
|
| Plasmapheresis | 1 | 2001 | 30 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2001 | 129 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2001 | 280 | 0.010 |
Why?
|
| Proline | 1 | 2001 | 78 | 0.010 |
Why?
|
| Tranexamic Acid | 1 | 2001 | 31 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 1019 | 0.010 |
Why?
|
| Lysine | 1 | 2001 | 166 | 0.010 |
Why?
|
| Radiology, Interventional | 1 | 2000 | 35 | 0.010 |
Why?
|
| Hypertriglyceridemia | 1 | 2001 | 118 | 0.010 |
Why?
|
| Pulsatile Flow | 1 | 2000 | 110 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 1323 | 0.010 |
Why?
|
| Normal Distribution | 1 | 1999 | 19 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 1613 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 9975 | 0.010 |
Why?
|
| Arginine | 1 | 2001 | 336 | 0.010 |
Why?
|
| Texas | 1 | 2008 | 3614 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2000 | 418 | 0.010 |
Why?
|
| Artifacts | 1 | 1999 | 104 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 2577 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2013 | 12853 | 0.010 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 1996 | 39 | 0.010 |
Why?
|
| Cricetinae | 1 | 1996 | 362 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1996 | 364 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1996 | 431 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 20734 | 0.010 |
Why?
|
| Cattle | 1 | 1996 | 501 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 782 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1999 | 2923 | 0.010 |
Why?
|
| Algorithms | 1 | 1999 | 1680 | 0.010 |
Why?
|
| Base Sequence | 1 | 1996 | 2767 | 0.010 |
Why?
|
| Gene Expression | 1 | 1996 | 1494 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 3507 | 0.010 |
Why?
|